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ABSTRACT 
Objective:  
To evaluate the potential of ADAMTS-4 (aggrecanase -1) activity in synovial fluid as a 
biomarker of knee injury and joint disease. 
Design:  
We have measured ADAMTS-4 activity in the synovial fluid of 170 orthopaedic patients 
with different degrees of joint pathology, using a commercial ADAMTS-4 fluorescence 
resonance energy transfer (FRET) substrate assay. Patients were classified at arthroscopy as 
(i) macroscopically normal, (ii) with an injury of the meniscus, anterior cruciate ligament or 
chondral/osteochondral defects or (iii) with osteoarthritis, and the influence of independent 
factors (age, patient group, effusion and synovial inflammation) on ADAMTS-4 activity 
levels was assessed. 
Results:  
In most patients (106/170) ADAMTS-4 activity was undetectable; ADAMTS-4 ranged from 
0-2.8ng/mL in synovial fluid from patients with an injury, 0-4.1ng/mL in osteoarthritic 
patients and 4.0-12.3ng/mL in patients with large effusions.  Four independent variables each 
significantly influenced ADAMTS-4 activity in synovial fluid (all p<0.001): age 
(concordance=0.69), presence of osteoarthritis (OA) (concordance=0.66), level of effusion 
(concordance=0.78) and inflammation (concordance=0.68). Not only did effusion influence 
the amount of ADAMTS-4 activity most strongly, but it also did this in an ordered manner 
(p<0.001).  
Conclusions.  
The main finding of this study is that ADAMTS-4 levels in synovial fluid are most strongly 
correlated with inflammation and severity of effusion in the knee.  Further study is required 
to determine if it could provide a useful tool to aid clinical diagnoses, indicate treatment, to 
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monitor progression of joint degeneration or osteoarthritis or alternatively the success of 
treatment. 
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INTRODUCTION 1 
The lack of valid biomarkers with a good relationship to joint structural pathology and symptomatic 2 
disease in individual patients is suggested as being partly responsible for the slow pace of 3 
innovation in developing novel, effective treatments for osteoarthritis1. Osteoarthritis (OA) of the 4 
knee can develop secondary to several disorders or injury in the joint and manifests as alteration of 5 
the joint structure, with progressive degradation of any or all of the tissues within it, such as 6 
cartilage, menisci and ligaments, as well as inflammation of the synovium and changes to the 7 
subchondral bone. Measuring biomarkers in fluids proximal to the site of the pathology, such as the 8 
synovial fluid in the knee, can be both more informative about the disease state in that particular 9 
joint and more sensitive, by virtue of their higher concentration than, for example, in blood or 10 
urine2,3. 11 
 12 
The best candidates for biomarkers in OA are suggested to be structural molecules or enzymes 13 
linked to cartilage, bone or synovium degradation4. One of the earliest and most striking 14 
biochemical changes to articular cartilage following injury or in degenerative joint diseases, such as 15 
OA, is degradation and loss of aggrecan.  Matrix metalloproteinases (MMPs) and aggrecanases (or 16 
A Disintegrin And Metalloprotease with Thrombospondin motifS (ADAMTS)) are the enzymes 17 
attributed with degrading the majority of the aggrecan. The most common ‘pathological’ 18 
ADAMTS-generated cleavage site in the aggrecan core protein is between the 392glutamate and the 19 
393alanine bond in the interglobular domain (reviewed in 5).  Many studies have been undertaken to 20 
develop and trial measuring the presence of these ‘neo-epitopes’ generated by enzyme activity to 21 
assess their potential as biomarkers with an ARGS-aggrecan assay showing considerable promise 22 
when measured in blood or synovial fluid6.   23 
 24 
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ADAMTS-5 (aggrecanase-2) is the predominant member of the ADAMTS family in mice models 1 
of degenerative joint disease or OA. The situation in humans is less clear and ADAMTS-4 2 
(aggrecanase-1) is likely to be a significant player5. In this study we have used a commercially 3 
available assay that can detect ADAMTS-4 activity independently of any contribution from 4 
ADAMTS-5.  We have measured the extent of ADAMTS-4 activity in synovial fluid from a cohort 5 
of heterogeneous patients, typical of those attending an orthopaedic outpatient clinic with different 6 
degrees of joint pathology, ranging from macroscopically normal to end stage OA. Our objective 7 
was to investigate if measuring ADAMTS-4 activity could provide a useful tool to aid the clinician.  8 
 9 
METHOD 10 
(i) Patient samples 11 
Synovial fluid was collected from patients presenting with clinical symptoms who were undergoing 12 
a routine diagnostic arthroscopy of the knee and consented to take part in this study (99\61\RJ 13 
approved by Shropshire Research Ethics Committee). Patients were classified into 3 groups 14 
according to their appearance at arthroscopy as assessed by the treating surgeon:  15 
(i) those with macroscopically normal knees and no obvious abnormality,  16 
(ii) those with injury of the meniscus, anterior cruciate ligament or chondral/osteochondral lesions 17 
and  18 
(iii) those with OA (i.e. with features, such as the presence of osteophytes and fragmenting articular 19 
cartilage in one or more compartments of the knee (Outerbridge Grade 37) or exposed subchondral 20 
bone (Outerbridge Grade 4). 21 
The presence of synovial inflammation was noted when the synovium was more reddened, swollen 22 
and convoluted than one would expect in a normal knee joint and the extent of joint effusion (none, 23 
small, moderate or large) was also assessed, using the sweep and patella tap tests8. A small effusion 24 
was recorded if the sweep test was positive but the patella tap test negative, a moderate effusion was 25 
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recorded if the sweep and patella tap tests were positive and a large effusion was recorded if sweep 1 
and patella tap tests were negative due to over-distention of the joint with effusion. 2 
 3 
The synovial fluid was collected by injecting 20mLs of 0.9% saline into the synovial cavity prior to 4 
arthroscopy; the knee was flexed and extended 20 times to allow mixing of the saline with the joint 5 
fluid. A needle was then reinserted into the knee and the synovial fluid aspirated; in the laboratory it 6 
was centrifuged for 15 minutes at 3000g and the supernatant stored at -80oC until use.   7 
 8 
Plasma was collected at the same time and a dilution factor of the synovial fluid (SF) was obtained 9 
by measuring the ratio of urea in SF:plasma (normally ~0.9 SF:serum)9.  Urea was measured with a 10 
colorimetric assay (QuantiChromTM Urea assay Kit (BioAssay Systems DIUR-500). 11 
 12 
(ii) ADAMTS-4 activity was measured in synovial fluid with the SensolyteTM 520 ADAMTS-4 13 
assay kit (Anaspec Inc) which uses a substrate for fluorescence resonance energy transfer (FRET), 14 
5-FAM and TAMRA as the donor-acceptor pair.  This acts as a substrate for active ADAMTS-4, 15 
which cleaves it into two separate fragments resulting in an increase of 5-FAM fluorescence which 16 
can be monitored at excitation and emission of 490nm and 520nm, respectively.  The ADAMTS-4 17 
assay was carried out according to the manufacturer’s instructions. Fifty microlitres of each sample 18 
of SF lavage were pipetted into wells of a 96-well black microplate (Costar®, Corning Life 19 
Sciences). In addition, a range of concentrations (2-10ng) of human recombinant ADAMTS-4 were 20 
pipetted into other wells to provide a standard curve to relate ADAMTS-4 activity in the SF 21 
samples to ng/mL of enzyme. There was also a well  containing assay buffer only, to provide a 22 
substrate control. Fifty microlitres of 5-FAM fluorescence reference standards (70-2500nM) were 23 
set up to calibrate the plate reader and act as an indicator of the amount of final product of the 24 
enzymatic reaction. The substrate solution (5-FAM/5-TAMRA) was added after pre-incubation at 25 
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37oC and the fluorescence intensity was measured following 60 minutes incubation at 37oC.  1 
Relating the amount of fluorescence intensity from each sample to that of the standard curve 2 
obtained from the recombinant ADAMTS-4 and multiplying it by the appropriate dilution factor for 3 
each SF sample, calculated the amount of ADAMTS-4 protein in each sample. 4 
 5 
(iii)   Statistics 6 
The lower limit of detection (LLOD) and lower limit of quantification (LLOQ) of ADAMTS-4 7 
were calculated from the standard deviation of blank samples and the slope of the calibration curve. 8 
QQ-plots were used to assess the distribution of continuous variables; age was normally distributed 9 
but ADAMTS-4 level was not. ADAMTS-4 levels were therefore summarised using medians and 10 
quartiles and compared between groups using non-parametric tests whereas parametric tests were 11 
used for age. Fisher’s exact test was used to compare distributions in categorical variables (e.g. 12 
presence of effusion by patient classification). ADAMTS-4 levels below the LLOD were classified 13 
as having 0ng/mL of ADAMTS-4. We used a censored or Tobit regression model10 to investigate 14 
the influence of the various independent factors (age, patient group, effusion and inflammation) on 15 
ADAMTS-4 levels, with the left limit set at the LLOD. This method requires a normal distribution 16 
for ADAMTS-4 levels, which was achieved by a logarithmic transformation, and minimises 17 
potential bias from the presence of a LLOD compared to traditionally used methods such as 18 
imputing half the LLOD for values below the LLOD10,11. The association between the independent 19 
factors (e.g. disease/injury, effusion and the presence of an inflamed synovium) and ADAMTS-4 20 
levels was assessed by the concordance c (a generalisation of the area under the curve (AUC) of a 21 
receiver operating characteristic (ROC) curve) and Nagelkerke’s R2, with 95% confidence intervals 22 
calculated on the basis of 999 bootstrap samples. 23 
 24 
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All statistical analysis was performed using R vs 3.0.3 (The R Foundation for Statistical 1 
Computing) using the packages “censReg” and “rms”. A p-value of 0.05 or below was assumed to 2 
denote statistical significance. In cases of multiple pairwise tests, p-values were adjusted using 3 
Holm’s procedure to maintain the 0.05 alpha-level. 4 
 5 
RESULTS 6 
Samples were collected from 170 patients, presenting with symptoms for varying times, ranging 7 
from 1 month to 16 years. The mean age of the macroscopically normal group was 28.6 years 8 
(8.5SD; n=22), the injury group 33.2 years (10.3SD; n=96) and the OA group 48.7 years (16.9SD; 9 
n=10). A number of patients combined an injury and OA (mean age 48.9 years ±11.6SD; n=31). 10 
Mean age differed significantly between patients with OA (alone or combined with injury) and 11 
those with ‘macroscopically normal’ joints (both p<0.001) or injured joints (both p<0.001, all 12 
pairwise t-tests). Eleven patients were not classified. Effusions were present in 6% of ‘normal’ 13 
joints, 40% of those with injuries, 71% of those with OA and 64% of those with injuries and OA. 14 
Effusions were less common in ‘macroscopically normal’ joints than any of the other types 15 
(p<0.05) but otherwise the incidence rates did not differ between the groups (p>0.25, all pairwise 16 
Fisher’s exact tests). Inflammation was noted in the knee joints of 25% of patients categorised as 17 
‘macroscopically normal’, 54% of the injury group, 67% of the OA group and 83% of those with 18 
injuries and OA. These rates were higher in joints with OA and injury compared to ‘normal’ joints 19 
or those with only injury (p<0.05), otherwise no differences were found (p>0.09, all pairwise 20 
Fisher’s exact tests).  21 
 22 
The lower limit of detection (LLOD) and lower limit of quantification (LLOQ) of the ADAMTS-4 23 
assay were 0.14ng/mL and 0.41ng/mL, respectively.  In most patients ADAMTS-4 activity did not 24 
reach detectable levels (106 out of 170). It was detectable in only 5% of samples from the ‘normal’ 25 
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group, in 33% of the injury group, in 60% of the OA group and in 67% of the combined injury and 1 
OA group. These rates were lower in the ‘normal’ group compared  to each of the three others 2 
(p<0.03) and lower in the injury group compared to the combined injury and OA group (p=0.004), 3 
but otherwise no differences were found (p>0.32, all pairwise Fisher’s exact tests). The measured 4 
level of ADAMTS-4 ranged between 0.2 and 34.9ng/mL SF (with a mean dilution factor for the SF 5 
samples of 3.6 (±2.2, range 1.1-12.1)). The median level of ADAMTS-4 was 0 ng/mL in the 6 
‘normal’ group (with one patient having a detectable amount of 0.3 ng/mL), 0 ng/mL in the injury 7 
group (range 0 to 29.8, with 32 patients having detectable levels), 1.2ng/mL in the OA samples 8 
(range 0 to 11.5, with 6 patients having detectable levels) and 1.3ng/mL in the combined injury and 9 
OA group (range 0 to 15.4, with 21 patients having detectable levels). There was significantly less 10 
ADAMTS-4 in the ‘normals’ than any of the other 3 patient groups and the injury group had less 11 
than the combined injury and OA group (both p<0.005; pairwise Mann-Whitney tests).  12 
 13 
Further analysis was simplified by separating the patient group qualifier into two: having OA 14 
(No/Yes) and having an injury (No/Chondral/Other; Table 1). No significant interaction effect of 15 
injury and OA on ADAMTS-4 levels was found (p=0.13; Tobit regression), justifying their further 16 
analysis as separately additive.  17 
 18 
Four independent variables each significantly influenced ADAMTS-4 levels (all p<0.001; Table 1, 19 
univariable analysis), namely age (concordance=0.69; Nagelkerke’s R2=0.10), having OA 20 
(concordance=0.66; Nagelkerke’s R2=0.11), effusion level (concordance=0.78; Nagelkerke’s 21 
R2=0.31) and presence of an inflamed synovium (concordance=0.68; Nagelkerke’s R2=0.11). 22 
Effusion had the best predictive value, with ADAMTS-4 levels rising in an ordered fashion with 23 
increased effusion (p<0.001, Jonckheere test; Fig. 1). In all, 14% of patients with no effusion, 36% 24 
of patients with a small effusion, 71% with a moderate effusion and 89% of those with a large 25 
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effusion had detectable levels of ADAMTS-4. The significance levels from the univariable Tobit 1 
regression and conventional non-parametric tests were in complete agreement (Table 1).  2 
 3 
The Tobit regression allows simultaneous investigation of multiple factors. Using all variables (full 4 
model; Table 1) suggested that three independent variables simultaneously significantly influenced 5 
ADAMTS-4 levels, namely age, level of effusion and having an inflamed synovium (reduced 6 
model, Table 1).  7 
 8 
DISCUSSION  9 
Several international efforts have been and are addressing the challenge of developing reliable, 10 
sensitive and specific biomarkers for OA. Examples are those by the European Society for Clinical 11 
Aspects of Osteoporosis and Osteoarthritis (ESCEO )4 and the Osteoarthritis Research Society 12 
International – Federal Drugs Agency (OARSI-FDA) initiative (http://oarsi.org/education/oarsi-13 
resources/fnih-osteoarthritis-biomarkers-consortium-project). Many groups have investigated the 14 
aggrecanase-generated neoepitope ARGS and assays are now available with great sensitivity12 15 
(down to 0.025pmol/mL6). This neoepitope can be measured not only in synovial fluid, but also in 16 
serum, plasma and urine, although results are less reliable in urine13;6. These assays, however, will 17 
not discriminate between the different forms of aggrecanase or ADAMTSs. The assay used in the 18 
present study measured activity of ADAMTS-4 (aggrecanase 1), with negligible cleavage of the 19 
FRET substrate by other members of the aggrecanase family, such as ADAMTS-1 and ADAMTS-20 
5. Another ADAMTS-4 assay, using a fluorescent ‘turn-on’ peptide conjugated to gold 21 
nanoparticles, demonstrated differential levels in acute and chronic joint injuries14.  22 
 23 
Our data suggests that effusion level, presence of synovial inflammation and age are the strongest 24 
determinants of level of ADAMTS-4, with injury or OA being less important. Mechanical loading 25 
is known to influence protease production, with the type of load switching production between 26 
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MMPs and aggrecanases, e.g. in rat intervertebral disc cells15. In a murine model of OA it has been 1 
shown that gene expression of proteases, including ADAMTS-4 and -5, is both rapid and highly 2 
mechanosensitive16.  This could explain the particularly strong relationship which we saw between 3 
effusion (and so swelling and increased pressure) in the joint and levels of ADAMTS-4 activity. 4 
Since ADAMTS-5 activity has not been assessed in the present study, it would be very interesting 5 
to measure this in the same or similar patient groups to determine if it also is increased with 6 
effusion. 7 
 8 
The relative levels of MMP and aggrecanase production in a joint may be important not only to how 9 
the joint tissues degrade but also to the individual’s ability to heal that injury and to their likelihood 10 
of developing OA. The DBA/1 strain of mice, which shows superior healing of injuries compared to 11 
the C57BL/6 strain, have less aggrecanase- but more MMP-induced aggrecan degradation than the 12 
C57BL/6 mice. In addition, the DBA/1 mice did not go on to develop subsequent signs of OA seen 13 
in the C57BL/6 mice17. 14 
 15 
If ADAMTS-4 proves useful as a biomarker, further information on the aetiopathogenesis of 16 
degenerative joint disease(s) may be possible by measuring a differentially spliced variant of 17 
ADAMTS-4 which appears to be produced predominantly by synovial cells, particularly in OA18. 18 
Certainly differentiating the tissue source is important for biomarkers as ADAMTS-4 has been 19 
shown to be involved in atherosclerosis and is produced by monocytes from patients with acute 20 
coronary syndrome19.  In addition, identification that ADAMTS-4 is a key player can help identify 21 
patients who might benefit from specific ADAMTS-4 inhibitors which are being developed. In 22 
terms of the BIPED classification of biomarkers20 (Burden of disease, Investigative, Prognostic, 23 
Efficacy of intervention or Diagnostic), evidence from this study suggests that ADAMTS-4 may 24 
prove useful for investigating the aetiopathogenesis of disease, making a diagnosis of joint effusion 25 
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or inflammation and perhaps assessing the burden of the disease. Conversely, our results also 1 
suggest that the extent of joint effusion might serve as a proxy for ADAMTS-4 levels in the joint 2 
fluid. The low concordance and large influence of confounding factors suggest ADAMTS-4 is 3 
unlikely to be suitable for OA diagnosis. 4 
 5 
There are, of course, several limitations to this study. One such is the way we related the relative 6 
fluorescent units created by the ADAMTS-4 in the SF samples to protein levels (ng/mL). We made 7 
the assumption that the kinetic curve would be the same for the recombinant ADAMTS-4 as it 8 
would be for the ADAMTS-4 in the biological samples, which of course it may not be. Different 9 
truncations and portions of the enzyme give different kinetics18. Variation in ADAMTS-4 structure, 10 
such as has been seen in OA joints, warrants further investigation in this matter in future studies. 11 
Another limitation is that we have only assessed ADAMTS-4 activity levels in comparison to a 12 
limited number of variables and observations and there are always more which could be made. For 13 
example, it would be interesting to determine if there was a relationship with the duration of 14 
patients’ symptoms. A further problem with the study is missing data. Ideally, we would have full 15 
data on all patients but as in most ‘real world’ clinical studies this was not possible and for some 16 
patients information is partly lacking (e.g. 11 patients (6.5%) were not classified by the surgeon into 17 
1 of the 3 categories at the time of the arthroscopic assessments). We believe that this data is 18 
missing completely at random as a consequence of busy clinics and therefore ‘missingness’ should 19 
not add bias to the assessments.  20 
 21 
In conclusion, identification and validation of reliable, sensitive biomarkers for injured or 22 
degenerate joints remain important goals, not only for patient diagnosis and prognosis, but also for 23 
furthering our understanding of disease progression and indicating therapies which can be applied at 24 
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a stage when the disease can be alleviated or modulated. We believe that measuring the level of 1 
ADAMTS-4 shows promise as a potentially useful biomarker and is worthy of further study. 2 
 3 
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Table 1.  Univariable and Multivariable predictors of ADAMTS-4 in synovial fluid of the knee 
 
 
n1 Median 
ADAMTS-4 
ng/mL 
 (IQR) 
p-
value2 
Coefficient3 
(95% CI) 
Concordance 
c (95% CI) 
Nagelkerke’s 
R2 (95% CI) 
p-
value4 
Univariable 
analysis 
       
Age 170 
  
0.08 (0.04-0.13) 0.69  
(0.62-0.78) 
0.10  
(0.03-0.19) 
<0.001 
OA 
   No 
   Yes 
159 
118 
41 
 
0.0 (0-0.3) 
1.3 (0-4.1) 
<0.001 
 
2.4 (1.2-3.6) 
0.66  
(0.59-0.73) 
0.11  
(0.04-0.22)  
<0.001 
Injury 
   None 
   Chondral 
   Other 
160 
32 
95 
33 
 
0 (0-0) 
0 (0-2.2) 
0 (0-2.8) 
0.10 
 
 
1.7 (0.2-3.3) 
1.4 (-0.4-3.3) 
0.58  
(0.52-0.65) 
0.03  
(0.00-0.12) 
0.10 
Effusion 
   No 
   Small 
   Moderate 
   Large 
122 
71 
28 
14 
9 
 
0.0 (0.0-0.0) 
0.0 (0.0-0.75) 
1.7 (0.2-3.4) 
8.5 (4.0-12.3) 
<0.0015 
 
 
1.8 (0.4-3.2) 
3.6 (1.9-5.3) 
5.4 (3.4-7.3) 
0.78  
(0.69-0.86) 
0.31  
(0.17-0.49) 
<0.001 
Inflammation 
   No 
   Yes 
144 
62 
82 
 
0.0 (0.0-0.0) 
0.2 (0.0-2.8) 
<0.001 
 
 
2.4 (1.1-3.6) 
0.68  
(0.60-0.76) 
0.11  
(0.03-0.24) 
<0.001 
Multivariable 
analysis 
       
Full model 
 
   Age 
   OA 
   Injury 
   Effusion 
   Inflammation 
104 
   
0.88  
(0.83-0.96) 
0.726 
0.65 
0.54 
0.79 
0.70 
0.46  
(0.36-0.66) 
0.136 
0.10 
0.01 
0.34 
0.15 
 
 
0.07 
0.64 
0.86 
<0.001 
0.04 
Reduced model 
 
   Age 
   Effusion 
      No 
      Small 
      Moderate 
      Large 
Inflammation 
   No 
   Yes 
106 
   
 
0.05 (0.01-0.09) 
 
 
1.7 (0.4-3.0) 
3.3 (1.7-4.8) 
4.4 (2.6-6.2) 
 
 
1.8 (0.5-3.0) 
0.88 
(0.83-0.95) 
0.726 
0.79 
 
 
 
 
0.71 
0.46 
(0.34-0.63) 
0.136 
0.34 
 
 
 
 
0.16 
 
 
0.02 
<0.001 
 
 
 
 
0.006 
 
Notes 1) Number of patients for each analysis, which vary due to data missingness 2) p-values from 
univariate non-parametric statistical analyses. 3) Coefficients from censored regression. 4) p-values 
from censored regression. 5) p-value from Jonckheere trend test. 6) Concordance and Nagelkerke’s 
R2 values for individual predictors in the full and reduced models are the univariable values when 
calculated using each model’s dataset. They are therefore NOT partial concordance or R2 
coefficients.  (IQR: interquartile range; CI: confidence intervals) 
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Figure 1.  
Levels of ADAMTS-4 (ng/mL) activity as a function of effusion size, shown as a boxplot. 
The thick horizontal lines represent the medians, the boxes represent upper and lower 
quartiles and the fences indicate the range up to 1.5 times the interquartile range below or 
above the lower or upper quartiles. Values higher than 1.5 times the interquartile range above 
the upper quartile are shown as open circles. The lower limit of detection of 0.14 ng/ml is 
shown as a horizontal line. 
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